OUR COMPANIES REDEFINE THE THERAPEUTICS OF TOMORROW
CARCELL BIOPHARMA INC.
Carcell Biopharma Inc. is an EVX company that develops next generation cell and gene therapies. Based in both Singapore & Shanghai, Carcell is co-founded by industry veterans with work experience across China, Singapore and Boston. Carcell is establishing an integrated R&D and manufacturing center in Shanghai Waigaoqiao, and also has a top-notch R&D team in Singapore. Carcell's two lead platforms are around engineered red blood cells for immuno-modulation, and non-viral gene delivery using lipid nanoparticles.
Headquartered in Singapore, Nuevocor focuses on developing AAV gene therapy vectors bearing therapeutic cargo for the treatment of genetically defined cardiac diseases with high unmet need. Leveraging its novel target discovery platform, and a genetic modifier approach to gene therapy, Nuevocor aims to meaningfully improve the quality of life for patients with presently incurable genetic heart disease.